Insulin Resistance in Kidney Disease: Is There a Distinct Role Separate from That of Diabetes or Obesity

CardioRenal Medicine

Volumn 8, Issue 1, 2017, Pages 41-49

  Whaley Connell, Adam ^a,b,c,d,e   Sowers, James R ^a,b,d,e  

^a Harry S Truman Memorial Veterans' Hospital   (China)

^b Diabetes and Cardiovascular Center   (China)

^c Department of Internal Medicine   (China)

^d Center for Osteoporosis and Metabolic Bone Diseases   (China)

^e University of Missouri   (United States)

Author keywords

Chronic kidney disease; Insulin resistance; Renin angiotensin aldosterone system

Indexed keywords

INSULIN RECEPTOR SUBSTRATE 1; PROTEIN KINASE B;

ADIPOSE TISSUE; DIABETES MELLITUS; DYSLIPIDEMIA; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY DISEASE; KIDNEY PLASMA FLOW; OBESITY; PANCREAS; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SKELETAL MUSCLE; SYSTOLIC BLOOD PRESSURE;

EID: 85030701029     PISSN: 16643828     EISSN: 16645502     Source Type: Journal    
DOI: 10.1159/000479801     Document Type: Review

References (68)

1. Chen J, Muntner P, Hamm LL, et al: The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004; 140: 167-174.
2. Yamagata K, Ishida K, Sairenchi T, et al: Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int 2007; 71: 159-166.
3. Soltani Z, Washco V, Morse S, Reisin E: The impacts of obesity on the cardiovascular and renal systems: cascade of events and therapeutic approaches. Curr Hypertens Rep 2015; 17: 7.
4. Pulakat L, DeMarco VG, Whaley-Connell A, Sowers JR: The impact of overnutrition on insulin metabolic signaling in the heart and the kidney. Cardiorenal Med 2011; 1: 102-112.
5. Aroor AR, McKarns S, Demarco VG, Jia G, Sowers JR: Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance. Metabolism 2013; 62: 1543-1552.
6. Ferdinand KC, Rodriguez F, Nasser SA, et al: Cardiorenal metabolic syndrome and cardiometabolic risks in minority populations. Cardiorenal Med 2014; 4: 1-11.
7. Zhan, J, Bottiglieri T, McCullough PA: The central role of endothelial dysfunction in cardiorenal syndrome. Cardiorenal Med 2017; 7: 104-117.
8. Shepard PR, Kahn BB: Glucose transporters and insulin action: implications for insulin resistance and diabetes mellitus. N Engl J Med 1999; 341: 248-257.
9. Muniyappa R, Sowers JR: Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord 2013; 14: 5-12.
10. Nistala R, Whaley-Connell A: Resistance to insulin and kidney disease in the cardiorenal metabolic syndrome; role for angiotensin II. Mol Cell Endocrinol 2013; 378: 53-58.
11. Marmy-Conus N, Hannan KM, Pearson RB: Ro 31-6045, the inactive analogue of the protein kinase C inhibitor Ro 31-8220, blocks in vivo activation of p70(s6k)/p85(s6k): implications for the analysis of S6K signalling. FEBS Lett 2002; 519: 135-140.
12. Bhandari BK, Feliers D, Duraisamy S, et al: Insulin regulation of protein translation repressor 4E-BP1, an eIF4E-binding protein, in renal epithelial cells. Kidney Int 2001; 59: 866-875.
13. Coward RJ, Welsh GI, Yang J, et al: The human glomerular podocyte is a novel target for insulin action. Diabetes 2005; 54: 3095-3102.
14. Das F, Dey N, Bera A, et al: MicroRNA-214 reduces insulin-like growth factor-1 (IGF-1) receptor expression and downstream mTORC1 signaling in renal carcinoma cells. J Biol Chem 2016; 291: 14662-14676.
15. Brosius FC, Coward RJ: Podocytes, signaling pathways, and vascular factors in diabetic kidney disease. Adv Chronic Kidney Dis 2014; 21: 304-310.
16. Chiu T, Santiskulvong C, Rozengurt E: EGF receptor transactivation mediates ANG II-stimulated mitogenesis in intestinal epithelial cells through the PI3-kinase/Akt/mTOR/p70S6K1 signaling pathway. Am J Physiol Gastrointest Liver Physiol 2005; 288:G182-G194.
17. Chen JK, Chen J, Thomas G, et al: S6 kinase 1 knockout inhibits uninephrectomy-or diabetes-induced renal hypertrophy. Am J Physiol Renal Physiol 2009; 297:F585-F593.
18. Yamakawa T, Tanaka S, Kamei J, et al: Phosphatidylinositol 3-kinase in angiotensin II-induced hypertrophy of vascular smooth muscle cells. Eur J Pharmacol 2003; 478: 39-46.
19. Oroszlan M, Bieri M, Ligeti N, et al: Sirolimus and everolimus reduce albumin endocytosis in proximal tubule cells via an angiotensin II-dependent pathway. Transpl Immunol 2010; 23: 125-132.
20. Whaley-Connell AT, Habibi J, Nistala R, et al: Mineralocorticoid receptor-dependent proximal tubule injury is mediated by a redox-sensitive mTOR/S6K1 pathway. Am J Nephrol 2012; 35: 90-100.
21. Whaley-Connell A, Habibi J, Panfili Z, et al: Angiotensin II activation of mTOR results in tubulointerstitial fibrosis through loss of N-cadherin. Am J Nephrol 2011; 34: 115-125.
22. Jia G, Aroor AR, Sowers JR: Arterial stiffness: a nexus between cardiac and renal disease. Cardiorenal Med 2014; 4: 60-71.
23. Aziz F, Chaudhary K: The triad of sleep apnea, hypertension, and chronic kidney disease: a spectrum of common pathology. Cardiorenal Med 2017; 7: 74-82.
24. Muniyappa R, Sowers JR: Endothelial insulin and IGF-1 receptors: when yes means NO. Diabetes 2012; 61: 2225-2227.
25. Rocchini AP, Marker P, Cervenka T: Time course of insulin resistance associated with feeding dogs a high-fat diet. Am J Physiol 1997; 272:E147-E154.
26. Pandey G, Makhija E, George N, et al: Insulin regulates nitric oxide production in the kidney collecting duct cells. J Biol Chem 2015; 290: 5582-5591.
27. Manhiani MM, Cormican M, Brands MW: Chronic sodium-retaining action of insulin in diabetic dogs. Am J Physiol Renal Physiol 2011; 300:F957-F965.
28. Bell TD, DiBona GF, Biemiller R, Brands MW: Continuously measured renal blood flow does not increase in diabetes if nitric oxide synthesis is blocked. Am J Physiol Renal Physiol 2008; 295:F1449-F1456.
29. Zeng G, Quon MJ: Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest 1996; 98: 894-898.
30. Kocyigit I, Taheri S, Sener EF, et al: Endothelial nitric oxide synthase gene expression is associated with hypertension in autosomal dominant polycystic kidney disease. Cardiorenal Med 2014; 4: 269-279.
31. DeFronzo RA, Alvestrand A, Smith D, et al: Insulin resistance in uremia. J Clin Invest 1981; 67: 563-568.
32. Landau M, Kurella-Tamura M, Shlipak MG, et al: Correlates of insulin resistance in older individuals with and without kidney disease. Nephrol Dial Transplant 2011; 26: 2814-2819.
33. Becker B, Kronenberg F, Kielstein JT, et al: Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol 2005; 16: 1091-1098.
34. Shinohara K, Shoji T, Emoto M, et al: Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 1894-1900.
35. Fliser D, Pacini G, Engelleiter R, et al: Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 1998; 53: 1343-1347.
36. Kobayashi S, Maesato K, Moriya H, et al: Insulin resistance in patients with chronic kidney disease. Am J Kidney Dis 2005; 45: 275-280.
37. Emoto M, Nishizawa Y, Maekawa K, et al: Insulin resistance in non-obese, non-insulin-dependent diabetic patients with diabetic nephropathy. Metabolism 1997; 46: 1013-1018.
38. Mykkanen L, Zaccaro DJ, Wagenknecht LE, et al: Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study. Diabetes 1998; 47: 793-800.
39. Chen J, Muntner P, Hamm LL, Fonseca V, Batuman V, Whelton PK, He J: Insulin resistance and risk of chronic kidney disease in non-diabetic US adults. J Am Soc Nephrol 2003; 14: 469-477.
40. Whaley-Connell A, Pavey BS, McCullough PA, Saab G, Li S, McFarlane SI, Chen SC, Vassalotti JA, Collins AJ, Bakris G, Sowers JR; KEEP Investigators: Dysglycemia predicts cardiovascular and kidney disease in the Kidney Early Evaluation Program. J Clin Hypertens (Greenwich) 2010; 12: 51-58.
41. Fox CS, Larson MG, Leip EP, et al: Predictors of new-onset kidney disease in a community-based population. JAMA 2004; 291: 844-850.
42. US Renal Data System: USRDS 2015 Chapter 1: CKD in the General Population.
43. Kramer HJ, Saranathan A, Luke A, et al: Increasing body mass index and obesity in the incident ESRD population. J Am Soc Nephrol 2006; 17: 1453-1459.
44. Iseki K, Ikemiya Y, Kinjo K, et al: Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int 2004; 65: 1870-1876.
45. Ejerblad E, Fored MC, Lindblad P, et al: Obesity and risk for chronic renal failure. J Am Soc Nephrol 2006; 17: 1695-1702.
46. Park J, Ahmadi SF, Streja E, et al: Obesity paradox in end-stage kidney disease patients. Prog Cardiovasc Dis 2014; 56: 415-425.
47. Degoulet P, Legrain M, Réach I, et al: Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. Nephron 1982; 31: 103-110.
48. Kopple JD, Zhu X, Lew NL, Lowrie EG: Body weight-for-height relationships predict mortality in maintenance hemodialysis patients. Kidney Int 1999; 56: 1136-1148.
49. Leavey SF, McCullough K, Hecking E, et al: Body mass index and mortality in healthier as compared with sicker haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2001; 16: 2386-2394.
50. Kalantar-Zadeh K, Kopple JD, Kilpatrick RD, et al: Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population. Am J Kidney Dis 2005; 46: 489-500.
51. Zammit AR, Katz MJ, Derby C, Bitzer M, Lipton RB: Metabolic syndrome and smoking are associated with future development of advanced chronic kidney disease in older adults. Cardiorenal Med 2016; 6: 108-115.
52. Hsu CY, McCulloch CE, Iribarren C, et al: Body mass index and risk for end-stage renal disease. Ann Intern Med 2006; 144: 21-28.
53. Praga M, Hernandez E, Herrero JC, et al: Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy. Kidney Int 2000; 58: 2111-2118.
54. Pinto-Sietsma SJ, Mulder J, Janssen WM, et al: Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. Ann Intern Med 2000; 133: 585-591.
55. Verhave JC, Hillege HL, Burgerhof JGM, et al: Impact of sodium intake on urinary albumin excretion is enhanced by obesity. J Am Soc Nephrol 2002; 13: 661-662.
56. De Jong PE, Verhave JC, Pinto-Sietsma SJ, Hillege HL; PREVEND study group: Obesity and target organ damage: the kidney. Int J Obes Relat Metab Disord 2002; 26(suppl 4):S21-S24.
57. Chagnac A, Weinstein T, Korzets A, et al: Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 2000; 278:F817-F822.
58. Porter LE, Hollenberg NK: Obesity, salt intake and renal perfusion in healthy humans. Hypertension 1998; 32: 144-148.
59. Reisin E, Messerli FG, Ventura HO, Frohlich ED: Renal haemodynamic studies in obesity hypertension. J Hypertens 1987; 5: 397-400.
60. Ribstein J, du Cailar G, Mimran A: Combined renal effects of overweight and hypertension. Hypertension 1995; 26: 610-615.
61. Chagnac A, Weinstein T, Herman M, et al: The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 2003; 14: 1480-1486.
62. Hall JE: Renal and cardiovascular mechanisms of hypertension. Hypertension 1994; 23: 381-394.
63. Obi Y, Kim T, Kovesdy CP, Amin AN, Kalantar-Zadeh K: Current and potential therapeutic strategies for hemodynamic cardiorenal syndrome. Cardiorenal Med 2016; 6: 83-98.
64. Jindal A, Brietzke S, Sowers JR: Obesity and the cardiorenal metabolic syndrome: therapeutic modalities and their efficacy in improving cardiovascular and renal risk factors. Cardiorenal Med 2012; 2: 314-317.
65. Henegar JR, Bigler SA, Henegar LK, et al: Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol 2001; 12: 1211-1217.
66. Kambham N, Markowitz GS, Valeri AM, et al: Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001; 59: 1498-1509.
67. Wisse BE: The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 2004; 15: 2792-2800.
68. Susic D, Frohlich ED: Hyperuricemia: a biomarker of renal hemodynamic impairment. Cardiorenal Med 2015; 5: 175-182.